Literature DB >> 27699528

Molecular Patterns and Biology of HPV-Associated HNSCC.

Ruud H Brakenhoff1, Steffen Wagner2, Jens P Klussmann2.   

Abstract

Head and neck cancer is the sixth most common cancer worldwide. The large majority are squamous cell carcinomas (HNSCC) that develop in the mucosal linings of the upper aerodigestive tract. These tumors develop either by exogenous carcinogen exposure (smoking, alcohol drinking) or by human papillomavirus (HPV) infection, particularly those in the oropharynx (OPSCC). HPV-positive (HPV+ve) and HPV-negative (HPV-ve) OPSCC are considered different disease entities. HPV+ve tumors are different at the molecular level and likely as a consequence have a much more favorable prognosis than HPV-ve tumors, despite their generally advanced stage at presentation. In general, HNSCCs develop in precancerous mucosal changes, and the apparent lack of precancerous HPV+ve mucosal changes is therefore remarkable. In this Chapter, head and neck carcinogenesis is discussed and the molecular differences between HPV+ve and HPV-ve tumors are outlined.

Entities:  

Keywords:  Epigenetics; Expression profile; Genetic alteration; Head and neck cancer; Human papillomavirus (HPV); MicroRNA (miRNA); Molecular carcinogenesis; Oropharynx

Mesh:

Year:  2017        PMID: 27699528     DOI: 10.1007/978-3-319-43580-0_3

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  8 in total

1.  Overexpression of TRMT12 may independently predict poor overall survival in patients with head and neck squamous cell carcinoma.

Authors:  Kai Wang; Mengmeng Zheng; Yuan Ren
Journal:  Onco Targets Ther       Date:  2019-09-05       Impact factor: 4.147

2.  M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB‑EGF.

Authors:  Enhui Fu; Tianyang Liu; Siyang Yu; Xiaohang Chen; Lianhao Song; Huihuang Lou; Fen Ma; Siwei Zhang; Sajjad Hussain; Junnan Guo; Ji Sun; Pingyang Yu; Xionghui Mao; Lanlan Wei
Journal:  Oncol Rep       Date:  2020-05-29       Impact factor: 3.906

Review 3.  Beyond MicroRNAs: Emerging Role of Other Non-Coding RNAs in HPV-Driven Cancers.

Authors:  Mariateresa Casarotto; Giuseppe Fanetti; Roberto Guerrieri; Elisa Palazzari; Valentina Lupato; Agostino Steffan; Jerry Polesel; Paolo Boscolo-Rizzo; Elisabetta Fratta
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

4.  EpCAM ectodomain EpEX is a ligand of EGFR that counteracts EGF-mediated epithelial-mesenchymal transition through modulation of phospho-ERK1/2 in head and neck cancers.

Authors:  Min Pan; Henrik Schinke; Elke Luxenburger; Gisela Kranz; Julius Shakhtour; Darko Libl; Yuanchi Huang; Aljaž Gaber; Miha Pavšič; Brigita Lenarčič; Julia Kitz; Mark Jakob; Sabina Schwenk-Zieger; Martin Canis; Julia Hess; Kristian Unger; Philipp Baumeister; Olivier Gires
Journal:  PLoS Biol       Date:  2018-09-27       Impact factor: 8.029

5.  MAGE-A11 Expression Predicts Patient Prognosis in Head and Neck Squamous Cell Carcinoma.

Authors:  Shiheng Jia; Minghui Zhang; Yanshu Li; Lan Zhang; Wei Dai
Journal:  Cancer Manag Res       Date:  2020-02-26       Impact factor: 3.989

6.  Head and Neck Squamous Cell Carcinoma: NT5E Could Be a Prognostic Biomarker.

Authors:  Yaoting Zhang; Sultan Kadasah; Jiaheng Xie; Dongsheng Gu
Journal:  Appl Bionics Biomech       Date:  2022-04-25       Impact factor: 1.664

Review 7.  Promising Biomarkers in Head and Neck Cancer: The Most Clinically Important miRNAs.

Authors:  Arsinoe C Thomaidou; Panagiota Batsaki; Maria Adamaki; Maria Goulielmaki; Constantin N Baxevanis; Vassilis Zoumpourlis; Sotirios P Fortis
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

8.  Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer.

Authors:  Tomasz W Rutkowski; Agnieszka M Mazurek; Mirosław Śnietura; Beata Hejduk; Maja Jędrzejewska; Barbara Bobek-Billewicz; Andrea d'Amico; Wojciech Pigłowski; Andrzej Wygoda; Krzysztof Składowski; Zofia Kołosza; Piotr Widłak
Journal:  J Transl Med       Date:  2020-04-15       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.